164 related articles for article (PubMed ID: 7495698)
1. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients.
Geisler J; Ekse D; Hösch S; Lønning PE
J Steroid Biochem Mol Biol; 1995 Nov; 55(2):193-5. PubMed ID: 7495698
[TBL] [Abstract][Full Text] [Related]
2. Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer.
Geisler J; Haarstad H; Gundersen S; Raabe N; Kvinnsland S; Lønning PE
J Endocrinol; 1995 Aug; 146(2):359-63. PubMed ID: 7561649
[TBL] [Abstract][Full Text] [Related]
3. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients.
Lønning PE; Johannessen DC; Lien EA; Ekse D; Fotsis T; Adlercreutz H
J Steroid Biochem Mol Biol; 1995 May; 52(5):491-6. PubMed ID: 7748814
[TBL] [Abstract][Full Text] [Related]
4. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
Ellmén J; Hakulinen P; Partanen A; Hayes DF
Breast Cancer Res Treat; 2003 Nov; 82(2):103-11. PubMed ID: 14692654
[TBL] [Abstract][Full Text] [Related]
5. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
[TBL] [Abstract][Full Text] [Related]
6. Droloxifene, a new antiestrogen. Hormonal influences in postmenopausal breast cancer patients.
Kvinnsland S
Am J Clin Oncol; 1991; 14 Suppl 2():S46-51. PubMed ID: 1962597
[TBL] [Abstract][Full Text] [Related]
7. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples.
Geisler J; Ekse D; Helle H; Duong NK; Lønning PE
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):90-5. PubMed ID: 18242079
[TBL] [Abstract][Full Text] [Related]
8. The minimal effective exemestane dose for endocrine activity in advanced breast cancer.
Bajetta E; Zilembo N; Noberasco C; Martinetti A; Mariani L; Ferrari L; Buzzoni R; Greco M; Bartoli C; Spagnoli I; Danesini GM; Artale S; Paolini J
Eur J Cancer; 1997 Apr; 33(4):587-91. PubMed ID: 9274439
[TBL] [Abstract][Full Text] [Related]
9. Sex hormones in postmenopausal women with breast cancer on tamoxifen.
Kostoglou-Athanassiou I; Ntalles K; Gogas J; Markopoulos C; Alevizou-Terzaki V; Athanassiou P; Georgiou E; Proukakis C
Horm Res; 1997; 47(3):116-20. PubMed ID: 9050950
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
11. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
12. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
13. Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer.
Kyvernitakis I; Albert US; Kalder M; Winarno AS; Hars O; Hadji P
Climacteric; 2015 Feb; 18(1):63-8. PubMed ID: 24884402
[TBL] [Abstract][Full Text] [Related]
14. A prospective study of endogenous estrogens and breast cancer in postmenopausal women.
Toniolo PG; Levitz M; Zeleniuch-Jacquotte A; Banerjee S; Koenig KL; Shore RE; Strax P; Pasternack BS
J Natl Cancer Inst; 1995 Feb; 87(3):190-7. PubMed ID: 7707406
[TBL] [Abstract][Full Text] [Related]
15. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
Harper-Wynne CL; Sacks NP; Shenton K; MacNeill FA; Sauven P; Laidlaw IJ; Rayter Z; Miall S; Howes A; Salter J; Hills MJ; Lowe FM; A'Hern R; Nasiri N; Doody D; Iqbal J; Dowsett M
J Clin Oncol; 2002 Feb; 20(4):1026-35. PubMed ID: 11844826
[TBL] [Abstract][Full Text] [Related]
17. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
18. The effect of short-term treatment with micronized estradiol on bone turnover and gonadotrophins in older men.
Taxel P; Kennedy D; Fall P; Willard A; Shoukri K; Clive J; Raisz LG
Endocr Res; 2000 Aug; 26(3):381-98. PubMed ID: 11019903
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen and partial oestrogen agonism in postmenopausal women.
Miodrag A; Ekelund P; Burton R; Castleden CM
Age Ageing; 1991 Jan; 20(1):52-4. PubMed ID: 1903020
[TBL] [Abstract][Full Text] [Related]
20. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]